2cureX’s CEO Ole Thastrup will join Folkemødet 2018 in Denmark

2cureX AB (“2cureX”) is invited by Bristol-Meyers Squibb Denmark to participate in a panel discussion at ”Folkemødet 2018” with amongst others the Minister of Industry, Business and Financial Affairs, Brian Mikkelsen. The panel discussion will focus on Innovation in Life Science and how to stimulate entrepreneurship and collaboration with academia to create the employers of the future. Folkemødet will be held in Allinge, Bornholm from June 14th to June 17th with the purpose of offering a democratic dialogue between politicians and stakeholders representing a broad spectrum of interest groups.

2cureX managed a successful IPO at Nasdaq First North in Stockholm November 24th 2017 and is preparing to launch its proprietary technology IndiTreat® in the Nordics, the United Kingdom and Germany. CEO Ole Thastrup says; “We feel honored to be seen as one of the new innovative Bio-Tech companies and to share our experience and best practices in building 2cureX, in order to help define prerequisites that will increase innovation and business opportunities within the Life Science sector

The Danish Folkemødet is organized by Foreningen Folkemødet and participation is free. For further information, please visit https://folkemoedet.dk/

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX.

For more information about 2cureX:

Ole Thastrup, CEO

E-mail: ot@2cureX.com

Phone: +45 22 11 53 99

URL: www.2curex.com 

Tags:

About Us

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients. IndiTreat® is currently being clinically validated in colorectal and ovarian cancer. The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

Subscribe

Quotes

We feel honored to be seen as one of the new innovative Bio-Tech companies and to share our experience and best practices in building 2cureX, in order to help define prerequisites that will increase innovation and business opportunities within the Life Science sector
Ole Thastrup, CEO